Pulmonary embolism: what does the new AHA/ACC 2026 guide add

Revista clinica espanola Pub Date : 2026-10-01 Epub Date: 2026-08-04 DOI:10.1016/j.rceng.2026.502610

Winnifer Briceño, David Jiménez

{"title":"Pulmonary embolism: what does the new AHA/ACC 2026 guide add","authors":"Winnifer Briceño, David Jiménez","doi":"10.1016/j.rceng.2026.502610","DOIUrl":null,"url":null,"abstract":"<div><div>Recently, the 2026 American Heart Association (<strong>AHA</strong>)/American College of Cardiology (<strong>ACC</strong>)/American College of Chest Physicians/American College of Chest Physicians/Society for Cardiovascular Angiography and Interventions/Society of Hospital Medicine/Society of Interventional Radiology/Society of Vascular Medicine/Society for Vascular Nursing Guideline for Evaluation and Management of Acute Pulmonary Embolism in Adults (AHA/ACC Acute PE Guideline) has been published. We aimed to critically evaluate the most significant sections of the guidelines. The new risk classification provides granularity, although the new categories require validation. We concur with the guidelines' recommendations regarding the use of low-molecular-weight heparins (parenteral treatment) and direct oral anticoagulants (oral treatment) as the preferred anticoagulants for the vast majority of patients with acute PE. Finally, the guidelines suggest reperfusion therapies for scenarios that currently lack robust scientific evidence; therefore, the results of ongoing clinical trials must be awaited to determine their precise indications.</div></div>","PeriodicalId":94354,"journal":{"name":"Revista clinica espanola","volume":"226 8","pages":"Article 502610"},"PeriodicalIF":0.0000,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista clinica espanola","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2254887426001219","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/8/4 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Recently, the 2026 American Heart Association (AHA)/American College of Cardiology (ACC)/American College of Chest Physicians/American College of Chest Physicians/Society for Cardiovascular Angiography and Interventions/Society of Hospital Medicine/Society of Interventional Radiology/Society of Vascular Medicine/Society for Vascular Nursing Guideline for Evaluation and Management of Acute Pulmonary Embolism in Adults (AHA/ACC Acute PE Guideline) has been published. We aimed to critically evaluate the most significant sections of the guidelines. The new risk classification provides granularity, although the new categories require validation. We concur with the guidelines' recommendations regarding the use of low-molecular-weight heparins (parenteral treatment) and direct oral anticoagulants (oral treatment) as the preferred anticoagulants for the vast majority of patients with acute PE. Finally, the guidelines suggest reperfusion therapies for scenarios that currently lack robust scientific evidence; therefore, the results of ongoing clinical trials must be awaited to determine their precise indications.

查看原文本刊更多论文

肺栓塞：新的AHA/ACC 2026指南增加了什么？

最近，2026年美国心脏协会(AHA)/美国心脏病学会(ACC)/美国胸科医师学会/美国胸科医师学会/心血管血管造影与介入学会/医院医学学会/介入放射学会/血管医学学会/血管护理学会《成人急性肺栓塞评估与管理指南》（AHA/ACC急性肺栓塞指南）发布。我们的目的是批判性地评估指南中最重要的部分。新的风险分类提供了粒度，尽管新的分类需要验证。我们同意指南关于使用低分子肝素（肠外治疗）和直接口服抗凝剂（口服治疗）作为绝大多数急性PE患者首选抗凝剂的建议。最后，指南建议在目前缺乏有力科学证据的情况下进行再灌注治疗；因此，必须等待正在进行的临床试验的结果，以确定其确切适应症。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Revista clinica espanola

自引率

0.00%

发文量